AU2022240609A1 - Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease - Google Patents

Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease Download PDF

Info

Publication number
AU2022240609A1
AU2022240609A1 AU2022240609A AU2022240609A AU2022240609A1 AU 2022240609 A1 AU2022240609 A1 AU 2022240609A1 AU 2022240609 A AU2022240609 A AU 2022240609A AU 2022240609 A AU2022240609 A AU 2022240609A AU 2022240609 A1 AU2022240609 A1 AU 2022240609A1
Authority
AU
Australia
Prior art keywords
compound
human
acth
cah
cortisol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022240609A
Other languages
English (en)
Inventor
Christine FERRARA-COOK
Alan S. Krasner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crinetics Pharmaceuticals Inc
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of AU2022240609A1 publication Critical patent/AU2022240609A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022240609A 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease Pending AU2022240609A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163163310P 2021-03-19 2021-03-19
US63/163,310 2021-03-19
US202263298571P 2022-01-11 2022-01-11
US63/298,571 2022-01-11
PCT/US2022/020543 WO2022197798A1 (en) 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Publications (1)

Publication Number Publication Date
AU2022240609A1 true AU2022240609A1 (en) 2023-09-28

Family

ID=83321094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022240609A Pending AU2022240609A1 (en) 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Country Status (10)

Country Link
US (2) US12280046B2 (https=)
EP (1) EP4308553A4 (https=)
JP (2) JP2024510260A (https=)
KR (1) KR20230159443A (https=)
AU (1) AU2022240609A1 (https=)
BR (1) BR112023018816A2 (https=)
CA (1) CA3211644A1 (https=)
IL (1) IL305952A (https=)
MX (1) MX2023010897A (https=)
WO (1) WO2022197798A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
CN120344523A (zh) * 2022-12-16 2025-07-18 克林提克斯医药股份有限公司 结晶黑皮质素亚型-2受体(mc2r)拮抗剂
WO2024242979A1 (en) * 2023-05-19 2024-11-28 Crinetics Pharmaceuticals, Inc. Compositions and methods for the treatment of congenital adrenal hyperplasia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
EP1465867A1 (en) 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20040058307A (ko) 2001-11-26 2004-07-03 쉐링 코포레이션 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
AU2003230367A1 (en) 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
RS53252B (sr) 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
CN1874777B (zh) 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2012163354A1 (en) 2011-05-31 2012-12-06 Linak A/S Actuator
EP4691556A3 (en) 2014-12-19 2026-04-29 H. Lundbeck A/S Humanized anti-acth antibodies and use thereof
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
WO2018003962A1 (ja) 2016-06-30 2018-01-04 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
WO2019014460A1 (en) 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CA3164117A1 (en) 2019-12-18 2021-06-24 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2023163945A1 (en) 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
CN120344523A (zh) 2022-12-16 2025-07-18 克林提克斯医药股份有限公司 结晶黑皮质素亚型-2受体(mc2r)拮抗剂

Also Published As

Publication number Publication date
US20250367190A1 (en) 2025-12-04
WO2022197798A1 (en) 2022-09-22
JP2026009936A (ja) 2026-01-21
EP4308553A1 (en) 2024-01-24
US20220313691A1 (en) 2022-10-06
IL305952A (en) 2023-11-01
CA3211644A1 (en) 2022-09-22
TW202302108A (zh) 2023-01-16
KR20230159443A (ko) 2023-11-21
MX2023010897A (es) 2023-09-27
US12280046B2 (en) 2025-04-22
BR112023018816A2 (pt) 2023-10-31
EP4308553A4 (en) 2025-01-22
JP2024510260A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
US12280046B2 (en) Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
Mazziotti et al. Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects
US20250281504A1 (en) Method for improving insulin insensitivity
Pia et al. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone
JP2020033354A (ja) 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
de Miguel Novoa et al. Guidelines for diagnosis and treatment of adrenal insufficiency in adults
US12290551B2 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
WO2012074774A1 (en) Methods for the treatment of fibromyalgia and chronic fatigue syndrome
WO2023163945A1 (en) Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
McGrath et al. Dimethoxy-etomidate: a nonhypnotic etomidate analog that potently inhibits steroidogenesis
RU2758386C2 (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
TWI916531B (zh) 用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑
EA052204B1 (ru) Применение антагониста рецептора меланокортина 2-го подтипа (mc2r) для лечения болезни кушинга или эктопического актг-синдрома (eas)
Bagdy The role of biogenic amines in neuroendocrine regulation in conscious rats
RU2302245C2 (ru) ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА
CN117043146A (zh) 用于治疗疾病的黑皮质素亚型-2受体（mc2r）拮抗剂
LU506495B1 (en) 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS
WO2024211343A1 (en) Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of acth-dependent cushing's syndrome
CA3122581C (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
JP2026513822A (ja) Ａｃｔｈ依存性クッシング症候群の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
Desire Pharmacologic Management
Grady Pharmacokinetics and pharmacodynamics of oral dexamethasone in healthy horses
MacLennan et al. Endocrine and Metabolic Effects of Drugs and Hormonal/Endocrine Manipulation of Non-endocrine Diseases